In this article, we will take a look at the 9 Best Gene-Editing Stocks to Buy According to Hedge Funds.

Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism. This concept was merely a theory for many years until the 1970s, when scientists were able to create recombinant DNA (rDNA) molecules. Fast-forward to the 2010s, and the CRISPR-Cas9 system mainstreamed gene editing, inspiring a commercialization boom. The first CRISPR-related company IPO’ed on NASDAQ in February 2016, and since then, the industry has grown in vibrancy and has attracted billions of investor dollars.

According to the Crispr Report, there were 1,031 active companies in the CRISPR ecosystem, 298 of which have raised about $35.8 billion over 1,200 funding rounds. And in terms of industry size, Research and Markets puts it at $10.8 billion by year-end 2025. The research firm estimates that the industry will expand at a 16.9% CAGR between 2025 and 2030, putting the valuation at nearly $24 billion in 2030.

And even with all that potential, Ark Invest’s Cathie Wood thinks that the gene editing space has much more to give, which hasn’t been discovered yet. She believes that combining AI with CRISPR and advances in other gene sequencing technologies could bring about a medical transformation. “This is the sleeper. It’s the most inefficiently priced part of the market,” Wood told the All-In Summit 2025 in September.

Perhaps this explains the high interest in gene editing stocks among hedge funds. For example, BlackRock bought over 980,000 more shares of a top gene editing company in Q3 2025. With this in mind, this post highlights some of the best names in this industry according to hedge fund interest.

Our Methodology

To compile our list of the 9 Best Gene‑Editing Stocks to Buy According to Hedge Funds, we first reviewed sector exposure through ETF holdings and recent media coverage. We focused on companies actively engaged in developing and commercializing gene‑editing technologies. We identified nine firms with positive upside potential and strong hedge fund support, drawing on Insider Monkey’s Q2 2025 database of over 983 funds. The list is arranged in ascending order according to hedge fund holdings.

Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

Best Gene‑Editing Stocks to Buy According to Hedge Funds

9. Editas Medicine Inc. (NASDAQ:EDIT)

Number of Hedge Fund Holders: 11

Editas Medicine (NASDAQ:EDIT) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, 2025, Clear Street raised its price target on Editas Medicine (NASDAQ:EDIT) to $4.60 from $4.00, while maintaining a Buy rating. The firm highlighted the company’s extended cash runway into the third quarter of 2027, supported by recent fundraising, and reaffirmed confidence in Editas’ lead program EDIT‑401, a gene editing therapy targeting LDL cholesterol.

Editas strengthened its balance sheet by raising $17.8 million through its ATM (at-the-market) offering in the third quarter and an additional $17.3 million in the fourth quarter, bringing its pro forma cash balance to $183 million. Clear Street noted this runway now extends beyond initial human data for EDIT‑401, providing financial flexibility to advance development milestones.

On the same day, Editas reported Q3 2025 results, posting EPS of –$0.28, slightly better than analyst estimates. Revenues rose to $7.5 million from $0.1 million in Q3 2024, driven by milestone recognition under its collaboration with Bristol Myers Squibb. CEO Gilmore O’Neill emphasized progress with EDIT‑401, citing preclinical data presented at AHA and ESGCT showing over 90% LDL cholesterol reduction in non‑human primates.

Editas Medicine (NASDAQ:EDIT) is a pioneering gene editing company focused on developing transformative in vivo therapies using CRISPR technology. Its pipeline includes EDIT‑401, with plans to file for IND/CTA by mid‑2026 and achieve human proof‑of‑concept data by year‑end 2026. The company holds exclusive licenses to the Broad Institute’s Cas12a and Cas9 patent estates, positioning it as a leader in precision gene editing.

8. Twist Bioscience Corporation (NASDAQ:TWST)

Number of Hedge Fund Holders: 23

Twist Bioscience Corporation (NASDAQ:TWST) is one of the best gene-editing stocks to buy according to hedge funds. On November 4, Steven Etoch, an analyst at Stephens, began coverage of Twist Bioscience Corporation (NASDAQ:TWST). Etoch assigned an Overweight rating on the stock and a $41 price target. The analyst cited Twist’s “differentiated, technology-driven DNA synthesis platform” as a key factor in the decision. The platform serves several markets, including drug discovery, next-generation sequencing (NGS), and synthetic biology. This platform is powered by silicon chip technology, which Etoch pointed out gives Twist advantages in cost, speed, and the scale of DNA production.

According to the analyst, Twist’s innovation spurred strong revenue growth – 22.7% over the past year and a five-year CAGR of 42%. Etoch noted further that while the gene editing landscape is competitive, Twist’s cost leadership and investments are helping it gain market share. The analyst expects the company to reach adjusted EBITDA break-even by the end of fiscal year 2026.

Etoch identified NGS as a major growth opportunity, particularly as its adoption expands in areas such as liquid biopsy and minimal residual disease (MRD) monitoring. He also cited expansion into adjacent markets as a way that Twist is strengthening its customer relationships.

Twist Bioscience Corporation (NASDAQ:TWST) is a synthetic biology company. It manufactures DNA at scale using a proprietary silicon-based platform. This enables rapid gene synthesis for applications in drug discovery, diagnostics, and precision medicine. Its main products are custom DNA sequences and gene libraries.

7. Krystal Biotech, Inc. (NASDAQ:KRYS)

Number of Hedge Fund Holders: 24

Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the best gene-editing stocks to buy according to hedge funds. On November 5, Evercore ISI’s Gavin Clark-Gartner affirmed a Buy rating on Krystal Biotech, Inc. (NASDAQ:KRYS) stock and set a price target of $218.

In a different update, Krystal released its Q3 2025 results on November 3, in which the quarter’s EPS came in at $2.66 per diluted share against the anticipated $1.09. Revenue touched $97.8 million from its VYJUVEK product, bringing total revenue since the US launch to over $623 million. The quarter’s net income was $79.4 million. According to management, this growth was driven by manufacturing efficiencies and a one-time non-cash tax benefit. Also, gross margin improved to 96% during the quarter, up from 93% in the prior quarter due to US product manufacturing optimizations, as noted by management. As a result, the company ended the quarter with over $864 million in cash and investments.

In terms of operations, management emphasized that expansion into Germany, France, and Japan is underway. There are also partnerships in the Middle East, Turkey, and Central and Eastern Europe. The company also confirmed its ongoing focus on increasing patient access for the treatment of Dystrophic Epidermolysis Bullosa (DEB) and expanding its global market presence.

Krystal Biotech, Inc. (NASDAQ:KRYS) is a biotechnology company. It develops and commercializes redosable gene therapies for rare and serious genetic diseases. Its first approved product, VYJUVEK, is the only FDA-approved redosable gene therapy for DEB, a severe skin disorder.

6. CRISPR Therapeutics AG (NASDAQ:CRSP)

Number of Hedge Fund Holders: 26

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, RBC Capital raised its price target for CRISPR Therapeutics AG (NASDAQ:CRSP) stock from $42 to $50. The firm kept the Sector Perform rating on the shares.

The analysts noted that CASGEVY, CRISPR’s leading product, missed its sales expectations in Q3 2025 – revenue from the product was $17 million, compared to a consensus estimate of $41 million. Also, the number of CASGEVY infusions fell from 16 in Q2 to 10 in Q3.​ But despite this underperformance, RBC Capital noted that Vertex Pharmaceuticals (CRISPR’s partner) projects over $100 million in total CASGEVY revenue for 2025. The analysts see this as an indication of more than $39 million in expected Q4 sales.

Separately, on the same day, Citizens affirmed its Market Outperform and an $86 price target on CRISPR stock, citing promising Phase 1 data for its CTX310 treatment. This treatment targets and destroys blood fats, specifically ANGPTL3, which contributes to the development of heart disease in individuals with cholesterol disorders. The analysts pointed out that Phase 1 data showed significant reductions in circulating ANGPTL3, supporting the in-vivo program’s promise.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a biopharmaceutical company. It develops transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing technology. Its main products include CASGEVY, the first FDA-approved CRISPR-based therapy for sickle cell disease and transfusion-dependent beta-thalassemia, as well as a pipeline of candidates, such as CTX310 for lipid disorders and CTX112 for oncology and autoimmune diseases.

5. Beam Therapeutics Inc. (NASDAQ:BEAM)

Number of Hedge Fund Holders: 31

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best gene-editing stocks to buy according to hedge funds. On November 14, Beam Therapeutics Inc. (NASDAQ:BEAM) announced Q3 2025 results in which it reported wider losses than last year’s. The reported net loss was $112.7 million ($1.10/share), higher than $96.7 million ($1.17/share) for Q3 2024.

Management attributed the losses to increased research and development (R&D) expenses ($109.8 million vs. $94.3 million in Q3 2024). This also includes expenses for in-process R&D from recent acquisitions. Despite these losses, Beam ended the quarter with $1.1 billion in cash, cash equivalents, and marketable securities, up from $850.7 million at year-end 2024. This strong cash position gives the company a projected runway into 2028, enough to fund its major clinical programs, management stated.

The company also reported significant clinical progress. For instance, management noted that enrollment and dosing in the pivotal BEAM-302 Phase 1/2 study for alpha-1 antitrypsin deficiency are progressing well. This trial is the first clinical effort to directly correct a disease-causing mutation in vivo, and management emphasized its status as a top priority. The BEACON Phase 1/2 trial for BEAM-101 in sickle cell disease reached a milestone with its updated data being accepted for presentation at the December American Society of Hematology (ASH) meeting. And dosing has begun for BEAM-103, an anti-CD117 monoclonal antibody in a healthy volunteer trial.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company. It develops precision genetic medicines using its proprietary base-editing technology. Its main products include investigational therapies such as BEAM-101 and BEAM-302.

4. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of Hedge Fund Holders: 33

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, Evercore ISI downgraded Intellia Therapeutics (NASDAQ:NTLA) from Outperform to In Line and cut its price target to $8 from $17, citing uncertainty around the company’s ATTR program timeline. While acknowledging promising efficacy updates, the firm noted that clarity on development milestones remains lacking, narrowing the path to value.

The downgrade followed Intellia’s November 10 announcement of three‑year follow‑up data from its Phase 1 trial of nexiguran ziclumeran (nex‑z) in transthyretin (ATTR) amyloidosis with cardiomyopathy. Results showed an 87% mean serum TTR reduction at 36 months with no waning effect, alongside stabilization or improvement in key biomarkers and functional status. Mortality rates were also significantly lower compared to a matched cohort, underscoring the therapy’s potential impact.

CEO John Leonard highlighted the durability of benefit even in advanced heart failure patients, calling the results “remarkable.” Reported adverse events were limited to mild infusion reactions and transaminase elevations. Intellia is working to resolve an FDA clinical hold on its Phase 3 MAGNITUDE trials, which remain critical for advancing nex‑z. Evercore suggested the upcoming HAELO results next spring could provide a clearer opportunity to reassess the company’s outlook.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a clinical‑stage gene editing company developing curative treatments through in vivo and engineered cell therapy programs. Its pipeline includes NTLA‑2001 for ATTR amyloidosis and NTLA‑2002 for hereditary angioedema, alongside collaborations with AvenCell, Kyverna, ONK Therapeutics, and ReCode to advance CAR‑T, NK cell, and genomic medicine platforms targeting cancer, autoimmune disorders, and cystic fibrosis.

3. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Number of Hedge Fund Holders: 53

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, Stifel maintained a Hold rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The firm also kept its price target at $445 for the stock. Stifel’s analysts referenced Vertex’s presentation of povetacicept (a dual BAFF/APRIL inhibitor) open-label Phase 1/2 results at the American Society of Nephrology (ASN) on November 8. They highlighted strong efficacy for both IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) indications.

Separately, Vertex presented its business and strategic pipeline developments at the UBS Global Healthcare Conference 2025 on November 11. The presentation covered the company’s progress in cystic fibrosis treatments, including updates on ALYFTREK, and its efforts to expand Medicaid coverage for these therapies. Management highlighted that povetacicept received Fast Track Designation from the FDA for pMN. Vertex also outlined its research pipeline addressing other serious diseases, including neuropathic pain, type 1 diabetes, and APOL1-mediated kidney disease.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company. It develops and commercializes therapies for serious diseases, with a primary focus on cystic fibrosis and genetic disorders. Its main products include Trikafta and other treatments for cystic fibrosis.

2. Natera, Inc. (NASDAQ:NTRA)

Number of Hedge Fund Holders: 66

Natera, Inc. (NASDAQ:NTRA) is one of the best gene-editing stocks to buy according to hedge funds. On November 7, Daniel Brennan, an analyst at TD Cowen, reiterated a Buy rating on Natera, Inc. (NASDAQ:NTRA) stock and lifted the price target to $240 from $215. Brennan cited a mix of factors, but key among them is Natera’s robust Q3 2025 results.

During the quarter, Natera’s sales beat estimates by 15%; management attributed the performance to “contributions from core business segments and favorable true-ups.​” The Signatera product was the most outstanding – it recorded a 78% year-over-year sales growth and achieved record quarterly volumes. Brennan described the performance as evidence of “strong market momentum”.

Independently of the analyst’s action, Natera’s management presented strategic growth initiatives and future prospects at the UBS Global Healthcare Conference 2025 on November 11. They stated that they processed approximately 893,600 tests in Q3 2025, up 15.2% year-over-year. Oncology testing volume reached 211,000 for the quarter, a 53.9% increase versus the prior year, and included a record sequential growth in clinical molecular residual disease (MRD) test units.​ Management also revealed plans to expand Medicare coverage to seven additional indications and progress with broader payer adoption.

Natera, Inc. (NASDAQ:NTRA) is a clinical genetic testing company. It specializes in non-invasive, cell-free DNA (cfDNA) technology, which allows detection and analysis of genetic material from a simple blood draw. Its main products include Panorama, a leading non-invasive prenatal test; Signatera, a personalized molecular residual disease assay for oncology; and Prospera, a cfDNA-based test for monitoring organ transplant rejection.

1. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 73

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, Canaccord Genuity analyst John Newman reaffirmed a Buy rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), setting a price target of $850.

Earlier on November 8, Regeneron Pharmaceuticals, Inc. reported positive results from Phase 2 clinical trials for its two investigational factor XI monoclonal antibodies, REGN7508 and REGN9933. The treatments target thrombosis, and the trials enrolled patients undergoing total knee replacement.

The company stated that both antibodies “demonstrated robust anti-clotting (antithrombotic) effects.” In particular, REGN7508 reduced the risk of postoperative venous thromboembolism (VTE) to 7.1%, outperforming apixaban (Eliquis), which has a rate of 12.4%. For REGN9933, the rate was 17.2%, numerically superior to enoxaparin’s 20.6%. Investigators highlighted that these results “confirm the role of factor XI in postoperative venous thromboembolism and suggest that these two distinct antibodies may enable flexibility for physicians to tailor anticoagulant therapy for patients with different risk profiles”.​ Regeneron said it plans to initiate broad Phase 3 trials for both factor XI antibodies before the end of this year.

Just a day earlier (November 7), the company had reported that its biologic drug Dupixent (dupilumab) – co-developed with Sanofi – achieved all primary and secondary endpoints in a Phase 3 trial for allergic fungal rhinosinusitis (AFRS), a rare sinus disease. The study assessed Dupixent in patients aged 6 years and older with AFRS. In the primary endpoint, sinus opacification scores (a radiological measure of nasal congestion) improved by 50.0% for patients administered Dupixent, compared to 9.8% for those who didn’t receive the treatment. In the secondary endpoint, the conditions of patients who received the therapy improved by 66.7% at 24 weeks and 80.6% at 52 weeks. The trial results will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 annual meeting.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company. It discovers, develops, and commercializes medicines for serious diseases, with a portfolio spanning ophthalmology, immunology, oncology, and rare conditions. Regeneron Pharmaceuticals is advancing genetic medicine through its Regeneron Genetics Center and proprietary platforms, focusing on in vivo CRISPR‑based gene editing in collaboration with Mammoth Biosciences.

While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best European Bank Stocks to Buy Now and 11 Best Solar Energy Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.